JP2015524822A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524822A5
JP2015524822A5 JP2015525605A JP2015525605A JP2015524822A5 JP 2015524822 A5 JP2015524822 A5 JP 2015524822A5 JP 2015525605 A JP2015525605 A JP 2015525605A JP 2015525605 A JP2015525605 A JP 2015525605A JP 2015524822 A5 JP2015524822 A5 JP 2015524822A5
Authority
JP
Japan
Prior art keywords
compound
formula
salt
converting
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015525605A
Other languages
English (en)
Japanese (ja)
Other versions
JP6147856B2 (ja
JP2015524822A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/053295 external-priority patent/WO2014022707A1/en
Publication of JP2015524822A publication Critical patent/JP2015524822A/ja
Publication of JP2015524822A5 publication Critical patent/JP2015524822A5/ja
Application granted granted Critical
Publication of JP6147856B2 publication Critical patent/JP6147856B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015525605A 2012-08-03 2013-08-01 インテグラーゼインヒビターを調製するためのプロセスおよび中間体 Expired - Fee Related JP6147856B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679475P 2012-08-03 2012-08-03
US61/679,475 2012-08-03
PCT/US2013/053295 WO2014022707A1 (en) 2012-08-03 2013-08-01 Process and intermediates for preparing integrase inhibitors

Publications (3)

Publication Number Publication Date
JP2015524822A JP2015524822A (ja) 2015-08-27
JP2015524822A5 true JP2015524822A5 (cg-RX-API-DMAC10.html) 2016-10-06
JP6147856B2 JP6147856B2 (ja) 2017-06-14

Family

ID=48980354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015525605A Expired - Fee Related JP6147856B2 (ja) 2012-08-03 2013-08-01 インテグラーゼインヒビターを調製するためのプロセスおよび中間体

Country Status (17)

Country Link
US (1) US8877931B2 (cg-RX-API-DMAC10.html)
EP (1) EP2880017B1 (cg-RX-API-DMAC10.html)
JP (1) JP6147856B2 (cg-RX-API-DMAC10.html)
KR (1) KR20150040340A (cg-RX-API-DMAC10.html)
CN (1) CN104520275B (cg-RX-API-DMAC10.html)
AU (1) AU2013296289B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015002275A2 (cg-RX-API-DMAC10.html)
CA (1) CA2878699C (cg-RX-API-DMAC10.html)
EA (1) EA026089B1 (cg-RX-API-DMAC10.html)
ES (1) ES2608860T3 (cg-RX-API-DMAC10.html)
IL (1) IL236618A (cg-RX-API-DMAC10.html)
IN (1) IN2015DN01688A (cg-RX-API-DMAC10.html)
MX (1) MX337094B (cg-RX-API-DMAC10.html)
NZ (1) NZ630199A (cg-RX-API-DMAC10.html)
PT (1) PT2880017T (cg-RX-API-DMAC10.html)
SG (1) SG11201500812QA (cg-RX-API-DMAC10.html)
WO (1) WO2014022707A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2015008510A0 (en) 2012-12-21 2015-06-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PL3252058T3 (pl) 2013-07-12 2021-07-19 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
NO2865735T3 (cg-RX-API-DMAC10.html) 2013-07-12 2018-07-21
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (cg-RX-API-DMAC10.html) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
ES2718410T3 (es) 2015-04-02 2019-07-01 Gilead Sciences Inc Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica
WO2021056193A1 (zh) * 2019-09-24 2021-04-01 凯莱英医药集团(天津)股份有限公司 一种苄基卤化锌及其衍生物的连续制备方法
CN112661698A (zh) * 2021-01-14 2021-04-16 浙江海森药业股份有限公司 一种艾维雷韦的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904108D0 (sv) * 1999-11-15 1999-11-15 New Pharma Research Ab Nya föreningar
MXPA03005338A (es) 2000-12-14 2003-10-06 Procter & Gamble Etapa de ciclizacion en el procedimiento de elaboracion de quinolonas y naftiridinas.
TW200300349A (en) 2001-11-19 2003-06-01 Sankyo Co A 4-oxoqinoline derivative
US20050104233A1 (en) 2002-05-31 2005-05-19 Shinji Kato Method of substituent introduction through halogen-metal exchange reaction
US6803469B2 (en) 2002-08-05 2004-10-12 The Procter & Gamble Company Process for preparing quinolone antibiotic intermediates
TW200409759A (en) 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols
EP3406596A1 (en) 2002-11-20 2018-11-28 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP1582524B1 (en) 2004-04-02 2008-08-13 Ludwig Maximilians Universität Method of preparing organomagnesium compounds
EP1582523A1 (en) 2004-04-02 2005-10-05 Ludwig-Maximilians-Universität München Method of preparing organomagnesium compounds
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US8633219B2 (en) 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
WO2007063869A1 (ja) 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
US20090233964A1 (en) 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
JP4669040B2 (ja) 2006-03-06 2011-04-13 日本たばこ産業株式会社 4−オキソキノリン化合物の製造方法
US8420821B2 (en) 2006-03-06 2013-04-16 Japan Tobacco Inc. Process for production of 4-oxoquinoline compound
TW200811153A (en) 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
CA2661943C (en) 2006-09-12 2015-11-03 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CN103480000A (zh) 2007-06-29 2014-01-01 吉里德科学公司 治疗用组合物和方法
WO2009006203A1 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa

Similar Documents

Publication Publication Date Title
JP2015524822A5 (cg-RX-API-DMAC10.html)
JP2019048806A5 (cg-RX-API-DMAC10.html)
JP2019194236A5 (cg-RX-API-DMAC10.html)
JP2010095546A5 (cg-RX-API-DMAC10.html)
JP2016520672A5 (cg-RX-API-DMAC10.html)
JP2018024670A5 (cg-RX-API-DMAC10.html)
JP2015042636A5 (ja) 有機化合物
JP2010174033A5 (cg-RX-API-DMAC10.html)
JP2015181191A5 (cg-RX-API-DMAC10.html)
JP2019207442A5 (cg-RX-API-DMAC10.html)
JP2013532130A5 (cg-RX-API-DMAC10.html)
RU2015148258A (ru) Силоксановое соединение и способ его получения
JP2020500916A5 (cg-RX-API-DMAC10.html)
PH12013500105A1 (en) Process for preparing antiviral compounds
RU2017102307A (ru) Способ получения синтетического пентапептида
MX2017003238A (es) Metodo para preparar 2'-o-fucosil-lactosa.
JP2018030858A5 (cg-RX-API-DMAC10.html)
WO2016038628A3 (en) A process for preparing olodaterol and intermediates thereof
JP2016513709A5 (cg-RX-API-DMAC10.html)
RU2014129937A (ru) Способы и промежуточные соединения для получения фармацевтических агентов
RU2015111236A (ru) Способ получения производного оксазола
JP2013043794A5 (cg-RX-API-DMAC10.html)
JP2018009003A5 (cg-RX-API-DMAC10.html)
JP2016517904A5 (cg-RX-API-DMAC10.html)
JP2018505179A5 (cg-RX-API-DMAC10.html)